Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Teniposide in lymphomas and leukemias.

P Sonneveld1

  • 1University Hospital Rotterdam Dijkzigt, The Netherlands.

Seminars in Oncology
|April 1, 1992
PubMed
Summary

Teniposide, a topoisomerase II inhibitor, shows limited use in leukemias and lymphomas despite its potency. Further clinical trials are warranted to explore its potential in treating these cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Myeloma Network Group review and consensus statement on primary plasma cell leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial.

European journal of cancer (Oxford, England : 1990)·2024
Same author

Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117].

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.

ESMO open·2022
Same author

Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322].

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>†</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Epipodophyllotoxins, etoposide and teniposide, are established treatments for leukemias and lymphomas.
  • Etoposide is widely used, while teniposide's role remains limited despite higher topoisomerase II inhibition and lower toxicity to progenitor cells.

Purpose of the Study:

  • To review the current role and potential of teniposide in treating leukemias and lymphomas.
  • To evaluate teniposide's efficacy and compare it with other agents and regimens.

Main Methods:

  • Literature review of clinical studies on teniposide in leukemias and lymphomas.
  • Analysis of data on remission rates, remission duration, and comparative efficacy.

Main Results:

  • Teniposide is established in childhood acute lymphoblastic leukemia (ALL) and shows promise in refractory adult ALL and acute monoblastic leukemia, though not superior to other regimens.
  • In non-Hodgkin's lymphoma, teniposide demonstrated comparable activity to vincristine.
  • Teniposide is used in bone marrow transplantation conditioning regimens for leukemias and lymphomas.

Conclusions:

  • Teniposide's clinical data in leukemias and lymphomas are limited.
  • Further clinical trials are necessary to fully establish teniposide's role and optimize its use in these hematologic malignancies.

Related Experiment Videos